The 6th World Symposium on Pulmonary Hypertension: what's old is new.

Autor:	Condon DF; Division of Pulmonary and Critical Care Medicine, Stanford University, Stanford, USA., Nickel NP; Division of Pulmonary and Critical Care Medicine, Stanford University, Stanford, USA., Anderson R; Division of Pulmonary and Critical Care Medicine, Stanford University, Stanford, USA., Mirza S; Division of Pulmonary and Critical Care Medicine, Stanford University, Stanford, USA.; Vera Moulton Wall Center for Pulmonary Vascular Research, Stanford University, Stanford, USA., de Jesus Perez VA; Division of Pulmonary and Critical Care Medicine, Stanford University, Stanford, USA.; Vera Moulton Wall Center for Pulmonary Vascular Research, Stanford University, Stanford, USA.
Jazyk:	angličtina
Zdroj:	F1000Research [F1000Res] 2019 Jun 19; Vol. 8. Date of Electronic Publication: 2019 Jun 19 (Print Publication: 2019).
DOI:	10.12688/f1000research.18811.1
Abstrakt:	In February 2018, the 6th World Symposium on Pulmonary Hypertension (WSPH) brought together experts from various disciplines to review the most relevant clinical and scientific advances in the field of PH over the last 5 years. Based on careful review and discussions by members of the different task forces, major revisions were made on the hemodynamic definition for various forms of PH and new genes were added to the list of genetic markers associated with pulmonary arterial hypertension (PAH) and pulmonary veno-occlusive disease. In addition, the use of risk stratification tools was encouraged as a strategy to reduce one-year mortality risk in PAH patients through early implementation of PAH therapies. While members of the medical community are still debating some of the proposed changes, the new WSPH guidelines advocate early diagnosis and initiation of combination therapy to reduce mortality and improve quality of life in patients with PH. Competing Interests: No competing interests were disclosed.Competing interests: Dr Simon is a consultant for Actelion, Complexa and received research funding from Novartis and NIH.Competing interests: Dr Sahay is serving as a speaker and consultant for Bayer, United Therapeutics and Actelion pharmaceuticals. He also has a Chest foundation grant.No competing interests were disclosed.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu